RNA for Precision Medicine – EVis Bioscience on Fortune Italia

We are pleased to share a new feature about EVis Bioscience AG published by Fortune Italia, highlighting how our technology is helping shape the future of precision medicine based on RNA therapeutics.

The article explores the scientific vision behind EVis: developing advanced non-viral delivery systems capable of directing therapeutic RNA safely and selectively to specific organs. This platform aims to overcome the limitations of current technologies and pave the way toward more effective treatments for rare diseases.

It also outlines the origins of the company, the international background of our CTO, Prof. Elita Montanari, and the path that led to the development of our novel RNA delivery strategy.

We invite you to read the full article to learn more about how EVis Bioscience is contributing to the evolution of advanced therapies:

➡️ RNA for Precision Medicine – Discovering EVis Bioscience AG (Fortune Italia)

Lastest Posts

  • La Repubblica news article

    We are proud to share that EVis Bioscience has been featured in la Repubblica‘s “Lab Revolution” series, highlighting our innovative approach to gene therapy for rare diseases. Founded in June 2024 by Italian researchers Elita Montanari with investor Tommaso Caselli, EVis Bioscience is a spin-off from ETH Zurich. Our mission is to develop next-generation non-viral…

  • Exosome RNA news article

    A recent study published on Exosome RNA introduces a novel method for efficiently loading nucleic acids into extracellular vesicles (EVs). This technique involves the spontaneous hybridization of EVs with preloaded non-lamellar liquid crystalline lipid nanoparticles (LCNPs) under physiological conditions, resulting in the formation of hybrid extracellular vesicles (HEVs). Key findings from the study include: This…